FHIR IG analytics| Package | hl7.fhir.us.uscdi-scd |
| Resource Type | CodeSystem |
| Id | CodeSystem-scd-observation-category-cs.json |
| FHIR Version | R4 |
| Source | https://build.fhir.org/ig/hlnconsulting/uscdi-scd-ig/CodeSystem-scd-observation-category-cs.html |
| URL | http://hl7.org/fhir/us/uscdi-scd/CodeSystem/scd-observation-category-cs |
| Version | 0.1.0 |
| Status | active |
| Date | 2026-09-11T00:10:30+00:00 |
| Name | SCDObservationCategoryCS |
| Title | SCD Observation Category Code System |
| Realm | us |
| Authority | hl7 |
| Description | Local code system defining observation category codes specific to Sickle Cell Disease clinical data exchange. These categories supplement the standard HL7 observation-category codes (laboratory, vital-signs, etc.) with SCD-specific sub-categories. TODO: Review against LOINC Part codes and US Core observation categories before finalizing. Consider submitting concepts to HL7 THO or LOINC. |
| Content | complete |
No resources found
No resources found
Note: links and images are rebased to the (stated) source
Generated Narrative: CodeSystem scd-observation-category-cs
This case-sensitive code system http://hl7.org/fhir/us/uscdi-scd/CodeSystem/scd-observation-category-cs defines the following codes:
{
"resourceType": "CodeSystem",
"id": "scd-observation-category-cs",
"text": {
"status": "generated",
"div": "<!-- snip (see above) -->"
},
"url": "http://hl7.org/fhir/us/uscdi-scd/CodeSystem/scd-observation-category-cs",
"version": "0.1.0",
"name": "SCDObservationCategoryCS",
"title": "SCD Observation Category Code System",
"status": "active",
"experimental": false,
"date": "2026-09-11T00:10:30+00:00",
"publisher": "HL7 International / Public Health",
"contact": [
{
"name": "HL7 International / Public Health",
"telecom": [
{
"system": "url",
"value": "https://www.hl7.org/Special/committees/pher"
},
{
"system": "email",
"value": "pher@lists.HL7.org"
}
]
},
{
"name": "HL7 Public Health Work Group",
"telecom": [
{
"system": "url",
"value": "http://www.hl7.org/Special/committees/pher"
},
{
"system": "email",
"value": "pher@lists.HL7.org"
}
]
}
],
"description": "Local code system defining observation category codes specific to Sickle\nCell Disease clinical data exchange. These categories supplement the\nstandard HL7 observation-category codes (laboratory, vital-signs, etc.)\nwith SCD-specific sub-categories.\n\nTODO: Review against LOINC Part codes and US Core observation categories\nbefore finalizing. Consider submitting concepts to HL7 THO or LOINC.",
"jurisdiction": [
{
"coding": [
{
"system": "urn:iso:std:iso:3166",
"code": "US",
"display": "United States of America"
}
]
}
],
"caseSensitive": true,
"content": "complete",
"count": 5,
"concept": [
{
"code": "hemoglobin-fractionation",
"display": "Hemoglobin Fractionation",
"definition": "Observation category for hemoglobin fractionation or electrophoresis results,\n including HbS%, HbF%, HbA%, HbA2%, and HbC% as measured by HPLC or\n capillary electrophoresis."
},
{
"code": "iron-overload-assessment",
"display": "Iron Overload Assessment",
"definition": "Observation category for measurements used to assess transfusional iron\n overload in SCD patients on chronic transfusion therapy, including serum\n ferritin, liver iron concentration (LIC), and transferrin saturation."
},
{
"code": "transfusion-medicine",
"display": "Transfusion Medicine",
"definition": "Observation category for immunohematology and transfusion medicine\n results, including ABO/Rh typing, extended red cell antigen phenotyping,\n antibody identification, and crossmatch results."
},
{
"code": "scd-pain-assessment",
"display": "SCD Pain Assessment",
"definition": "Observation category for pain severity assessments in the context of\n Sickle Cell Disease, including numeric rating scale (NRS) scores for\n vaso-occlusive crisis monitoring."
},
{
"code": "scd-disease-monitoring",
"display": "SCD Disease Monitoring",
"definition": "Observation category for disease-specific monitoring observations in\n SCD that do not fit other standard categories, including functional\n asplenia markers, organ function screening, and complication surveillance."
}
]
}